Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
The identification of pO 2 lowering agents as transient hypoxia-inducers is disclosed herein. Provided is a method of enhancing the efficacy of a hypoxia-sensitive agent in a subject, by administering to the subject a therapeutically effective amount of the hypoxia-sensitive agent and a therapeutically effective amount of a pO 2 lowering agent. Methods of treating a subject with a tumor, by administering to the subject a therapeutically effective amount of a pO 2 lowering agent and a therapeutically effective amount of a hypoxia-sensitive agent are also disclosed.
1. A method for enhancing the efficacy of a hypoxia activated prodrug in a subject having a tumor, comprising
administering to the subject a therapeutically effective amount of the hypoxia activated prodrug and a therapeutically effective amount of CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, wherein the amount of the CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, administered is sufficient to transiently enhance hypoxia of the tumor,
wherein the hypoxia activated prodrug is phosphorodiamidic acid (TH-302), and wherein the tumor is a pancreatic cancer, a colon cancer or a squamous cell carcinoma,
thereby enhancing the efficacy of the hypoxia activated prodrug in the subject.
2. The method of claim 1 , wherein the tumor is the squamos cell carcinoma.
3. The method of claim 1 , wherein the CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, decreases the oxygen partial pressure in the tumor.
4. The method of claim 1 , wherein the CH 3 COCOO − , 13 CH 3 COCOO − and/or CH 3 COCOOH, is administered in a single dose.
5. The method of claim 1 , wherein the CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, is administered in multiple doses.
6. The method of claim 1 , wherein the CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, is administered prior to administering the hypoxia activated prodrug.
7. The method of claim 1 , wherein the CH 3 COCOO − , 13 CH 3 COCOO − , and/or CH 3 COCOOH, is administered concurrently with the hypoxia activated prodrug.
8. The method of claim 1 , further comprising measuring the partial pressure of oxygen in the tumor after administration of CH 3 COCOO − , 13 CH 3 COCOO − and CH 3 COCOOH, and detecting a decrease in the partial pressure of oxygen.
9. The method of claim 1 , wherein the tumor is the colon cancer.
10. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of CH 3 COCOO − or 13 CH 3 COCOO − .
11. The method of claim 2 , wherein the cancer is the pancreatic cancer.
12. A method for treating a tumor in a subject, comprising
administering to the subject a therapeutically effective amount of phosphorodiamidic acid (TH-302); and
administering to the subject a therapeutically effective amount of CH 3 COCOOH, CH 3 COCOO − , or 13 CH 3 COCOO − wherein the therapeutically effective amount is sufficient to transiently enhance hypoxia of the tumor,
thereby enhancing the efficacy of phosphorodiamidic acid (TH-302) and treating the tumor in the subject, wherein the tumor is pancreatic cancer, colon cancer or squamous cell carcinoma, and wherein treating the tumor comprises reducing growth of the tumor.
13. The method of claim 12 , wherein the tumor is the pancreatic cancer.
14. The method of claim 12 , wherein the tumor is the squamous cell carcinoma.
15. The method of claim 12 , comprising administering to the subject the therapeutically effective amount of 13 CH 3 COCOO − .
16. The method of claim 12 , comprising administering to the subject the therapeutically effective amount of CH 3 COCOO − .
17. The method of claim 12 , wherein the tumor is the colon cancer.